Dr. Dreicer on Trial Endpoints in Prostate Cancer

Robert Dreicer, MD
Published: Tuesday, Apr 29, 2014

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

In early disease settings, the trial endpoints that are needed for regulatory approval take longer to achieve, Dreicer says. The ability to hit the survival endpoint in a disease where patients can then subsequently receive other active drug may make the survival endpoint very difficult to reach.

Dreicer believes that survival endpoints will remain difficult to reach in some disease stages until intermediate endpoints are routinely applied in prostate cancer.
 
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

In early disease settings, the trial endpoints that are needed for regulatory approval take longer to achieve, Dreicer says. The ability to hit the survival endpoint in a disease where patients can then subsequently receive other active drug may make the survival endpoint very difficult to reach.

Dreicer believes that survival endpoints will remain difficult to reach in some disease stages until intermediate endpoints are routinely applied in prostate cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x